Antibiotics for Hand Infections
Hand infections are treated based on whether infection is purulent, whether there is cellulitis without abscess, and whether MRSA risk is present. Antibiotic choice also depends on mechanism (e.g., human bite) and host risk factors. [1][2]
Infectious Entities Commonly Requiring Antibiotics
- Paronychia or felon without abscess is treated with conservative care and short-course oral antibiotics when infection is not mild or is persistent. [2]
- Purulent skin and soft tissue infection (abscess, purulent drainage) requires incision and drainage when feasible. [1]
- Cellulitis without abscess is treated with oral beta-lactam antibiotics targeting streptococci and methicillin-susceptible Staphylococcus aureus (MSSA) when MRSA is not suspected. [1]
- Human bite or clenched-fist injury requires antibiotic regimens that cover oral flora including Eikenella corrodens. [2]
Medication Selection Algorithm
When MRSA is not suspected
- Beta-lactam monotherapy for cellulitis without abscess is recommended (examples: cephalexin; amoxicillin-clavulanate when polymicrobial coverage is needed). [1][2]
When MRSA is suspected or confirmed
- Doxycycline, clindamycin, or trimethoprim-sulfamethoxazole (TMP-SMX) are recommended for MRSA-associated purulent SSTI. [1]
When infection involves bite-related organisms
- Amoxicillin-clavulanate is used for bite wounds that require broader coverage. [2]
When systemic severity or deep infection is present
- Hospital evaluation and parenteral therapy are used when there are systemic signs or concern for deeper structure involvement. [1][2]
Key Evidence Supporting This Recommendation
- The IDSA SSTI guideline recommends drainage for purulent SSTI when feasible and recommends MRSA-active agents (doxycycline, clindamycin, TMP-SMX) when MRSA is suspected or confirmed. [1]
- The IDSA SSTI guideline states that activity of doxycycline and TMP-SMX against beta-hemolytic streptococci is not known, and recommends beta-lactam monotherapy for cellulitis without abscess or purulence when MRSA is not suspected. [1]
Monotherapy Versus Combination Therapy
- Cellulitis without abscess is treated with beta-lactam monotherapy when MRSA is not suspected. [1]
- MRSA coverage is achieved with single-agent MRSA-active therapy (doxycycline, clindamycin, or TMP-SMX) in appropriate clinical scenarios described in the IDSA SSTI guideline. [1]
- Polymicrobial coverage for bites is addressed by selecting agents active against expected bite organisms rather than adding MRSA agents by default. [2]
Initiation Thresholds and Practical Indications
- Oral antibiotics are used for early hand infections without abscess formation when conservative measures alone are insufficient. [2]
- Incision and drainage is used for abscesses or purulent collections when present. [1][2]
- Escalation of care is indicated for systemic symptoms or concern for deeper infection, with inpatient management and parenteral antibiotics considered. [1][2]
Common Pitfalls to Avoid
- Omitting drainage when a true abscess is present is avoided because purulent SSTI generally requires incision and drainage. [1]
- Using MRSA-only coverage for nonpurulent cellulitis is avoided when MRSA is not suspected because doxycycline and TMP-SMX have uncertain activity against beta-hemolytic streptococci and IDSA favors beta-lactam monotherapy in this setting. [1]
- Treating after adequate drainage as a default is avoided because antibiotics are often not needed after successful drainage in uncomplicated cases per hand-infection guidance. [2]
Targets and Goals of Therapy
- Therapy goals are infection control with appropriate antimicrobial coverage based on suspected organisms and timely procedural management for purulence. [1][2]
- Reassessment is indicated when there is inadequate clinical response to chosen therapy to address resistant organisms or occult deeper infection. [1][2]